iBio, Inc. (IBIO)
Largest Insider Buys in Sector
IBIO Stock Price History Chart
IBIO Stock Performance
About iBio, Inc.
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Insider Activity of iBio, Inc.
Over the last 12 months, insiders at iBio, Inc. have bought $0 and sold $35,556 worth of iBio, Inc. stock.
On average, over the past 5 years, insiders at iBio, Inc. have bought $0 and sold $19.7M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,200,000 shares for transaction amount of $1.98M was made by Eastern Capital LTD (10 percent owner) on 2018‑07‑12.
List of Insider Buy and Sell Transactions, iBio, Inc.
| 2023-11-01 | Sale | Brenner Martin | See Remarks | 4,881 0.0175% | $0.27 | $1,296 | -1.14% | |
| 2023-10-03 | Sale | Brenner Martin | See Remarks | 5,267 0.0187% | $0.30 | $1,592 | -1.14% | |
| 2023-10-02 | Sale | Brenner Martin | See Remarks | 4,215 0.0154% | $0.31 | $1,311 | -1.14% | |
| 2023-08-28 | Sale | Brenner Martin | See Remarks | 5,011 0.0211% | $0.31 | $1,529 | -1.14% | |
| 2023-07-27 | Sale | Brenner Martin | See Remarks | 4,515 0.0337% | $0.51 | $2,308 | -1.14% | |
| 2023-07-12 | Sale | Brenner Martin | See Remarks | 47,020 0.3517% | $0.59 | $27,521 | -1.14% | |
| 2023-06-21 | Sale | Brenner Martin | See Remarks | 4,184 0.0322% | $0.68 | $2,849 | -1.14% | |
| 2023-05-22 | Sale | Brenner Martin | See Remarks | 4,182 0.032% | $0.94 | $3,910 | -1.14% | |
| 2023-04-24 | Sale | Brenner Martin | See Remarks | 4,382 0.0338% | $1.20 | $5,258 | -1.14% | |
| 2023-03-23 | Sale | Brenner Martin | See Remarks | 5,213 0.0411% | $2.13 | $11,112 | -70.24% | |
| 2023-02-21 | Sale | Brenner Martin | See Remarks | 3,976 0.0322% | $1.77 | $7,038 | -58.43% | |
| 2022-03-10 | Sale | Lutz Robert Matthew | See Remarks | 24,625 0.0112% | $0.35 | $8,510 | -31.43% | |
| 2021-12-07 | Sale | Maddux Randy Joe | Chief Operating Officer | 37,243 0.0164% | $0.68 | $25,444 | -59.15% | |
| 2020-08-11 | Sale | Eastern Capital LTD | 10 percent owner | 15.86M 10.3338% | $2.92 | $46.33M | -43.30% | |
| 2020-08-10 | Sale | Eastern Capital LTD | 10 percent owner | 7.26M 4.7429% | $3.91 | $28.43M | -57.45% | |
| 2020-08-07 | Sale | Eastern Capital LTD | 10 percent owner | 1.36M 0.8401% | $3.83 | $5.19M | -58.42% | |
| 2020-08-06 | Sale | Eastern Capital LTD | 10 percent owner | 2.77M 1.7544% | $4.18 | $11.57M | -61.08% | |
| 2020-08-05 | Sale | Eastern Capital LTD | 10 percent owner | 900,000 0.5628% | $4.46 | $4.01M | -64.01% | |
| 2020-08-04 | Sale | Eastern Capital LTD | 10 percent owner | 600,000 0.3697% | $4.39 | $2.64M | -64.01% | |
| 2020-06-04 | Sale | ERWIN ROBERT L | President | 28,268 0.0455% | $1.71 | $48,338 | +1.18% |
Institutional Investor Ownership
No records found… | |||||||